<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03059823</url>
  </required_header>
  <id_info>
    <org_study_id>INCMGA 0012-101</org_study_id>
    <nct_id>NCT03059823</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of INCMGA00012 in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Incyte Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goal of this Phase 1 study is to characterize the safety and tolerability of&#xD;
      INCMGA00012 and establish the maximum tolerated dose (MTD) of INCMGA00012 administered on&#xD;
      either every two week or every four week schedules of administration among patients with&#xD;
      solid tumors. Pharmacokinetics, pharmacodynamics, and the anti-tumor activity of INCMGA00012&#xD;
      will also be assessed.&#xD;
&#xD;
      The purpose of Amendment 5 is to obtain additional safety experience at the newly defined&#xD;
      recommended Phase 2 dose of 500 mg every 4 weeks in patients with endometrial cancer,&#xD;
      specifically either microsatellite instability-high (MSI-H) or mismatch repair deficient&#xD;
      (dMMR). Additionally, every 3 week (Q3W) flat-dosing will be studied in an additional tumor&#xD;
      agnostic cohort.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a Phase 1, open-label, dose escalation and cohort expansion study designed to&#xD;
      characterize the safety, tolerability, PK, PD, immunogenicity, and preliminary anti-tumor&#xD;
      activity of INCMGA00012 administered IV every 2, 3, or 4 weeks in patients with&#xD;
      relapsed/refractory, unresectable locally advanced or metastatic solid tumors.&#xD;
&#xD;
      In the initial phase of the study, two dose schedules will be assessed in dose escalation,&#xD;
      once every two weeks and once every four weeks administration of single agent INCMGA00012.&#xD;
      Following the establishment of an MTD, additional patients will enroll in expansion cohorts&#xD;
      of specific tumor types and/or INCMGA00012 dose.&#xD;
&#xD;
      The Cohort Expansion Phase will include tumor-specific cohorts, consisting of patients with&#xD;
      endometrial cancer (unselected [up to n = 35] and MSI-H or dMMR [up to n = 70]), cervical&#xD;
      cancer (up to n = 35), sarcoma (up to n = 35), non-small cell lung cancer (NSCLC) (up to n =&#xD;
      35), and 3 cohorts of any tumor histology (tumor-agnostic) (up to n = 15) who will receive&#xD;
      flat dosing: 1 cohort treated with INCMGA00012 500 mg Q4W, 1 cohort with INCMGA00012 750 mg&#xD;
      Q4W, and 1 cohort treated with INCMGA00012 375 mg Q3W.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 15, 2016</start_date>
  <completion_date type="Anticipated">June 29, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 26, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE v4.03</measure>
    <time_frame>24 months</time_frame>
    <description>Safety is based on evaluation of adverse events (AEs) and serious adverse events (SAEs) from the time of study drug administration through the End of Study visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MTD</measure>
    <time_frame>24 months</time_frame>
    <description>Maximum Tolerated Dose of INCMGA00012</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC</measure>
    <time_frame>24 months</time_frame>
    <description>Area Under the Plasma Concentration versus Time Curve of INCMGA00012</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>24 months</time_frame>
    <description>Maximum Plasma Concentration of INCMGA00012</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>24 months</time_frame>
    <description>Time to reach maximum (peak) plasma concentration of INCMGA00012</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ctrough</measure>
    <time_frame>24 months</time_frame>
    <description>Trough plasma concentration of INCMGA00012</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total body clearance of the drug from plasma (CL) of INCMGA00012</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vss</measure>
    <time_frame>24 months</time_frame>
    <description>Apparent volume of distribution at steady state of INCMGA00012</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>24 months</time_frame>
    <description>Terminal half-life of INCMGA00012</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ADA</measure>
    <time_frame>24 months</time_frame>
    <description>Percent of patients with anti-drug antibody</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">322</enrollment>
  <condition>Locally Advanced Solid Tumors</condition>
  <condition>Metastatic Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Dose Escalation-Q2W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INCMGA00012 treatment once every 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation- Q3W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INCMGA00012 treatment once every 3 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation- Q4W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INCMGA00012 treatment once every 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INCMGA00012 treatment for locally advanced or metastatic solid tumors.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>retifanlimab</intervention_name>
    <description>Anti-PD-1 monoclonal antibody</description>
    <arm_group_label>Dose Escalation- Q3W</arm_group_label>
    <arm_group_label>Dose Escalation- Q4W</arm_group_label>
    <arm_group_label>Dose Escalation-Q2W</arm_group_label>
    <arm_group_label>Expansion Cohort</arm_group_label>
    <other_name>INCMGA0012</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Histologically proven, locally advanced unresectable or metastatic solid tumors for whom no&#xD;
        approved therapy with demonstrated clinical benefit is available or standard treatment was&#xD;
        declined. Patients enrolled to Cohort H (endometrial cancer 500 mg Q4W) must have MSI-H or&#xD;
        dMMR endometrial cancer, as determined by a local laboratory using IHC or PCR methods and&#xD;
        must also have tissue (fresh or archival) available for central confirmation of diagnosis&#xD;
&#xD;
          -  Expansion cohort(s): Progression during or following at least 1, and up to 5, previous&#xD;
             systemic therapies, consistent with the standard of care for the specific tumor type.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&#xD;
&#xD;
          -  Life expectancy â‰¥ 12 weeks&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  Acceptable laboratory parameters&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Symptomatic central nervous system (CNS) metastases.&#xD;
&#xD;
          -  For Cohort Expansion, patients who have previously received an immune checkpoint&#xD;
             inhibitor (e.g., anti-PD-L1, anti-PD-1, anti-CTLA-4) are not eligible for this study.&#xD;
&#xD;
          -  Patients with any history of known or suspected autoimmune disease with the specific&#xD;
             exceptions of vitiligo, resolved childhood atopic dermatitis, psoriasis not requiring&#xD;
             systemic treatment (within the past 2 years), and patients with a history of Grave's&#xD;
             disease that are now euthyroid clinically and by laboratory testing.&#xD;
&#xD;
          -  Treatment with any systemic anti-neoplastic therapy, or investigational therapy within&#xD;
             the 4 weeks prior to the initiation of study drug administration.&#xD;
&#xD;
          -  Treatment with radiation therapy within 2 weeks prior to the initiation of study drug&#xD;
             administration.&#xD;
&#xD;
          -  Clinically significant cardiovascular disease&#xD;
&#xD;
          -  Clinically significant pulmonary compromise, including a requirement for supplemental&#xD;
             oxygen use to maintain adequate oxygenation.&#xD;
&#xD;
          -  Presence of active pneumonitis or history of non-infectious pneumonitis.&#xD;
&#xD;
          -  Clinically significant gastrointestinal disorders&#xD;
&#xD;
          -  Evidence of active viral, bacterial, or systemic fungal infection requiring parenteral&#xD;
             treatment within 7 days prior to the initiation of study drug. Patients requiring any&#xD;
             systemic antiviral, antifungal, or antibacterial therapy for active infection must&#xD;
             have completed treatment no less than one week prior to the initiation of study drug&#xD;
&#xD;
          -  Known history of positive testing for human immunodeficiency virus or history of&#xD;
             acquired immune deficiency syndrome.&#xD;
&#xD;
          -  Known history of hepatitis B or hepatitis C infection or known positive test for&#xD;
             hepatitis B surface antigen, hepatitis B core antigen, or hepatitis C polymerase chain&#xD;
             reaction (PCR)&#xD;
&#xD;
          -  Vaccination with any live virus vaccine within 4 weeks prior to the initiation of&#xD;
             study drug administration. Inactivated annual influenza vaccination is allowed&#xD;
&#xD;
          -  Dementia or altered mental status that would preclude understanding and rendering of&#xD;
             informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Incyte Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Incyte Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Incyte Corporation Call Center (US)</last_name>
    <phone>1.855.463.3463</phone>
    <email>medinfo@incyte.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Incyte Corporation Call Center (ex-US)</last_name>
    <phone>+800 00027423</phone>
    <email>globalmedinfo@incyte.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Honor Health Research Institute</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>South Texas Accelerated Research Therapeutics</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49546</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of Nj</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Carolina Bio-Oncology Institute, Pllc</name>
      <address>
        <city>Huntersville</city>
        <state>North Carolina</state>
        <zip>28078</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Texas Md Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>South Texas Accelerated Research Therapeutics</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University Massey Cancer Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chris Obrien Lifehouse</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>02050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St Vincent'S Hospital Sydney</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>02010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis (Uz) Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>03000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Liege - Sart Tilman</name>
      <address>
        <city>Liege</city>
        <zip>04000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Complex Oncology Center ? Burgas Eood</name>
      <address>
        <city>Burgas</city>
        <zip>08000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Mc Women'S Health-Nadezhda Eood</name>
      <address>
        <city>Sofia</city>
        <zip>01330</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Acibadem Cityclinica Mhat Tokuda</name>
      <address>
        <city>Sofia</city>
        <zip>01407</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Umhat in Oncology</name>
      <address>
        <city>Sofia</city>
        <zip>01756</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sun Yat-Sen Memorial Hospital Sun Yat-Sen University</name>
      <address>
        <city>Guangzhou</city>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Qilu Hospital of Shandong University</name>
      <address>
        <city>Jinan</city>
        <zip>250000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xian Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xiamen University</name>
      <address>
        <city>Xiamen</city>
        <zip>361000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hostipal</name>
      <address>
        <city>Zhengzhou</city>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Docrates Cancer Center</name>
      <address>
        <city>Helsinki</city>
        <zip>00180</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <zip>20521</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>HÃ¯Â¿Â½PITAUX UNIVERSITAIRES DE GENEVE</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Diaconesses Croix Saint-Simon</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre de Lutte Contre Le Cancer - Institut de Cancerologie de L'Ouest - Rene Gauducheau</name>
      <address>
        <city>Saint-herblain</city>
        <zip>44800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire Du Cancer de Toulouse Oncopole</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Charite Universitaetsmedizin Berlin - Campus Charite Mitte</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>CHARITE - UNIVERSITÃ¯Â¿Â½TSMEDIZIN BERLIN</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Clinic Carl Gustav Carus Technical University Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University Medical Center Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stadtische Klinikum Munchen ? Neuperlach Klinik Fur Hamatologie Und Onkologie</name>
      <address>
        <city>Munchen</city>
        <zip>81737</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Grosshadern Munich</name>
      <address>
        <city>Munich</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Ospedali Riuniti</name>
      <address>
        <city>Ancona</city>
        <zip>60126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fondazione Del Piemonte Per L'Oncologia Ircc Candiolo</name>
      <address>
        <city>Candiolo</city>
        <zip>10060</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori Irccs Fondazione Pascale</name>
      <address>
        <city>Naples</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Agostino Gemelli Universita Cattolica Del Sacro Cuore</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Riga East University Hospsital</name>
      <address>
        <city>Riga</city>
        <zip>LV1079</zip>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-08660</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Auckland</city>
        <zip>01023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Wellington Hospital</name>
      <address>
        <city>Wellington</city>
        <zip>06021</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>SZPITALE WOJEWÃ¯Â¿Â½DZKIE W GDYNI SPÃ¯Â¿Â½LKA Z OGRANICZONA ODPOWIEDZIALNOSCIA</name>
      <address>
        <city>Gdynia</city>
        <zip>81-519</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Krakow, Department of Oncology</name>
      <address>
        <city>Krakow</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Ko-Med Centra Kliniczne Osrodek Badan Klinicznych W Lublinie</name>
      <address>
        <city>Lublin</city>
        <zip>20-362</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Zaklad Opieki Zdrowotnej Msw Z W-McO W Olsztynie</name>
      <address>
        <city>Olsztyn</city>
        <zip>10-357</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Biovirtus Research Site</name>
      <address>
        <city>Otwock</city>
        <zip>05-400</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Szpital Kliniczny Przemienienia Panskiego</name>
      <address>
        <city>Poznan</city>
        <zip>06056</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Katedra I Klinika Onkologii Um W Poznaniu Oddzial Ginekologii Onkologicznej</name>
      <address>
        <city>Poznan</city>
        <zip>60-569</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Medical University of Warsaw - 2Nd Department Obstetric and Gynecology</name>
      <address>
        <city>Warsaw</city>
        <zip>00-315</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Centrum Onkologii - Instytut Im. Marii Sklodowskiej - Curie</name>
      <address>
        <city>Warsaw</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Vall D Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro Integral Oncologico Clara Campal (Ciocc)</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Multifield Clinical Hospital No 4</name>
      <address>
        <city>Dnipro</city>
        <zip>49102</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Oncology Center Facility of State Higher Educational Institution</name>
      <address>
        <city>Ivano-frankivsk</city>
        <zip>76000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rmi Sumy Regional Clinical Oncology Dispensary</name>
      <address>
        <city>Sumy</city>
        <zip>40030</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uzhgorod National University Clinical Base Uzhgorod Central City Clinical Hospital</name>
      <address>
        <city>Uzhgorod</city>
        <zip>08800</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Podillia Regional Center of Oncology - Chemotherapy Department</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Sraha Cannon Research Institute</name>
      <address>
        <city>London</city>
        <zip>W1G 6AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Christie Nhs Foundation Trust Uk</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden Nhs Foundation Trust - Chelsea</name>
      <address>
        <city>Sutton</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>China</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 9, 2017</study_first_submitted>
  <study_first_submitted_qc>February 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2017</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Solid tumors</keyword>
  <keyword>Metastatic cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

